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Introduction
T cell responses are controlled by multiple receptors: while costim-
ulatory receptors ensure optimal T cell activation and prolifer-
ation to generate a protective immune response, coinhibitory or 
checkpoint receptors dampen effector T cell responses to prevent 
immunopathology and autoimmunity. In addition to their expres-
sion on effector T cells, coinhibitory receptors are also expressed 
on Tregs, where they serve to promote Treg suppressor function, 
thus further contributing to control of the immune response. How 
coinhibitory receptors in these different cell types achieve their 
effects and the relative contribution of their functions to immune 
regulation is still largely unknown.
Achieving a better understanding of how individual coin-
hibitory receptors regulate the immune response is critical, as 
therapeutic strategies that interfere with signaling through these 
receptors are currently at the forefront of treatment for cancer and 
other chronic diseases such as chronic viral infection. In chronic 
diseases, the dysregulated expression of coinhibitory receptors on 
effector T cells is associated with a dysfunctional effector pheno-
type characterized by deficits in proliferative capacity, secretion 
of proinflammatory cytokines, and cytotoxicity (1). Moreover, the 
high expression levels of coinhibitory receptors on Tregs is associ-
ated with potent Treg suppressor function. Accordingly, therapies 
that target the coinhibitory receptors CTLA-4 and PD-1 are prov-
ing successful in treating cancer (2). The mechanisms by which 
these therapies achieve their effects are still being elucidated. In 
this regard, a recent study showed that the response to PD-1 block-
ade is much higher if there are preexisting CD8+ T cells within the 
tumor tissue (3); however, whether the recovery of productive 
immunity after treatment is due to direct modulation of effector T 
cell function or modulation of Treg function is unclear.
TIGIT is a novel coinhibitory receptor that, together with 
CD226 (DNAM-1), comprises a pathway that closely parallels 
the CD28/CTLA-4 pathway. Similar to CD28 and CTLA-4, 
CD226 and TIGIT share ligands (CD112 and CD155) (4–6), and 
engagement of CD226 enhances T cell activation (7, 8), while 
engagement of TIGIT inhibits T cell responses (4, 9, 10). CD226 
is expressed on NK cells and CD8+ T cells and is preferentially 
expressed on IFN-γ–producing CD4+ Th1 T cells (11). TIGIT is 
upregulated on CD4+ and CD8+ T cells upon activation and is also 
found on NK cells, memory T cells, follicular Th cells, and on a 
subset of Tregs (4, 5, 9, 10, 12).
Over the past few years, TIGIT has emerged as an important 
coinhibitory receptor. An initial study indicated that TIGIT inhib-
its T cell responses indirectly by triggering CD155 in DCs, thereby 
preventing DC maturation and inducing production of the immu-
nosuppressive cytokine IL-10 (4). However, recent studies show 
that TIGIT has a T cell–intrinsic inhibitory function in that TIGIT 
ligation directly inhibits T cell proliferation and cytokine production 
in CD4+ T cells (9, 10). Similarly, TIGIT ligation also suppresses the 
cytolytic activity of NK cells (6). Indeed, TIGIT contains 2 immuno-
receptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic 
tail (4, 10). These motifs have been shown to mediate recruitment of 
the phosphatase SHIP-1 (13), thus providing a mechanism by which 
TIGIT can act cell intrinsically to dampen activating signals. In addi-
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murine cancer cell lines. We found that the TIGIT ligands CD112 
and CD155 were highly expressed on multiple murine cancer cell 
lines, while TIGIT itself was not (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI81187DS1). Similarly, expression of CD155 and CD112 has also 
been reported in human melanoma cell lines (17). We next exam-
ined TIGIT expression on lymphocytes in mice bearing B16F10 
melanoma tumors. We observed that while TIGIT was expressed 
at low levels on T cells in the spleen and tumor-draining lymph 
nodes (DLNs), it was markedly enriched on both CD4+ and CD8+ 
T cells that infiltrated melanoma tumors (Figure 1A). We further 
found that TIGIT was similarly enriched on the CD4+ and CD8+ 
T cells that infiltrated CT26 colon carcinoma (Supplemental Fig-
ure 2A). As TIGIT is constitutively expressed on a subset of Tregs 
(4, 10, 12), we further examined whether TIGIT expression was 
enriched on Tregs within CD4+ TILs. We found that TIGIT was 
highly expressed on FOXP3+ Tregs compared with that observed 
on FOXP3– CD4+ TILs in both B16 melanoma (Figure 1B) and 
CT26 colon carcinoma (Supplemental Figure 2B). Thus, TIGIT 
expression was enriched on both CD8+ T cells and Tregs in 2 dif-
ferent preclinical cancer models, and, importantly, TIGIT+ lym-
phocytes were mostly confined to tumor tissue.
TIGIT+ CD8+ TILs display a dysfunctional phenotype. Coinhibi-
tory receptors are often expressed on T cells that exhibit a dysfunc-
tional phenotype. We therefore examined whether TIGIT+ CD8+ 
TILs display defects in effector functions. We found that TIGIT+ 
CD8+ TILs were poor producers of IL-2 and TNF-α but produced 
similar levels of IFN-γ compared with TIGIT– CD8+ TILs (Figure 
2A). Interestingly, while TIGIT+ CD8+ TILs exhibited deficits in 
proinflammatory cytokine production, we found that they had sig-
nificantly increased production of the immune-suppressive cytok-
ine IL-10 compared with TIGIT– CD8+ TILs. Moreover, we found 
that TIGIT+ CD8+ TILs exhibited a reduced capacity to degranu-
tion to direct regulation of effector T cell responses, recent studies 
show that TIGIT marks a subset of Tregs that exhibit heightened 
expression of known Treg effector molecules and heightened sup-
pressive capacity in vitro (12, 14). Most interestingly, TIGIT+ Tregs 
exhibit a specialized function, that of selectively suppressing proin-
flammatory Th1 and Th17 responses but sparing Th2 responses (12), 
thus supporting a role for TIGIT in directing Treg function.
The absence of TIGIT has been shown to exacerbate experi-
mental autoimmune encephalomyelitis, while TIGIT engagement 
has been shown to ameliorate collagen-induced arthritis (9, 10). 
Recently, blockade of TIGIT has been shown to synergize with 
PD-1/PD-L1 blockade to enhance antitumor CD8+ T cell responses 
in both humans and mice (15, 16). These observations support an 
important inhibitory role for TIGIT in vivo; however, they do not 
address the role of TIGIT in effector T cells versus Tregs in reg-
ulating antitumor immunity. Here, we dissect the role of TIGIT 
in cancer, where coinhibitory receptor expression on effector T 
cells is associated with the development of T cell dysfunction, 
and expression on Tregs is associated with potent Treg suppres-
sor function. We found that TIGIT is uniquely enriched on tumor- 
infiltrating lymphocytes (TILs), where it marks the most dysfunc-
tional CD8+ T cells and FOXP3+ tumor tissue Tregs. Importantly, 
we show that it is not the function of TIGIT in effector CD8+ T cells 
but rather its function in FOXP3+ Tregs that plays a critical role in 
dampening antitumor immune responses. Our data shed light on 
the mechanisms by which the coinhibitory receptor TIGIT deter-
mines immune responses in chronic disease settings and highlight 
the therapeutic value of targeting TIGIT in cancer.
Results
TIGIT expression is upregulated on TILs. Before examining a poten-
tial role for TIGIT in regulating antitumor T cell responses, we 
first examined the expression of TIGIT and its ligands on several 
Figure 1. TIGIT is enriched on TILs. Spleen, tumor DLNs, and 
TILs were harvested from WT Foxp3-GFP–KI mice (n = 5) 
bearing B16F10 melanoma tumors and stained with Abs against 
CD4, CD8, and TIGIT. (A) Left panels: representative flow 
cytometric data showing TIGIT expression on CD4+ and CD8+ T 
cells in spleen, DLNs, and TILs. Right panel: frequency ± SEM 
of TIGIT+ cells. ****P < 0.0001 by 1-way ANOVA and Tukey’s 
multiple comparisons test. (B) Left panels: representative 
flow cytometric data showing TIGIT expression in CD4+ FOXP3– 
(GFP–) and CD4+ FOXP3+ (GFP+) in TILs. Right panel: frequency ± 
SEM of TIGIT+ FOXP3– and FOXP3+ cells. CD4+ FOXP3+ percent-
ages within total CD4+ T cells were 32.46% ± 4.27%. Data are 
representative of 2 to 3 experiments. ****P < 0.0001 by 1-way 
ANOVA and Tukey’s multiple comparisons test comparing 
TIGIT+ FOXP3+ cells across the indicated tissues.
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lation within natural Tregs that exhibits a highly activated and 
suppressive Treg phenotype (12). Accordingly, we examined 
whether TIGIT+ Tregs in tumor tissue exhibited a more activated 
phenotype than did their TIGIT– Treg counterparts. For this, we 
determined the expression profile of more than 200 immuno-
logically relevant genes in TIGIT+ versus TIGIT– Tregs isolated 
from melanoma tumors using NanoString nCounter technology. 
We identified several genes that were differentially regulated 
in TIGIT+ relative to TIGIT– Tregs isolated from tumor tissue 
(Figure 3A and complete list in Supplemental Table 1). Many 
of these genes are consistent with those previously reported as 
differentially regulated in TIGIT+ Tregs relative to TIGIT– Tregs 
in naive mice (12). Similarly upregulated genes included genes 
that encode coinhibitory receptors (Pdcd1, which encodes PD-1, 
Lag3, Ctla4, and Havcr2, which encodes TIM-3), chemokines 
and chemokine receptors (Ccr2, Ccr5, Ccr8, Cxcr3, Cxcr6, and 
Ccl5), transcription factors (Rora, Prdm1, Id2, Tbx21, and Foxp3), 
and the effector molecule Il10. Similarly downregulated genes 
included Bcl2, Tcf7, and Ifngr2.
Among the most highly upregulated genes in TIGIT+ Tregs 
from TILs was Il10 (Figure 3A). As IL-10 is an important Treg 
effector molecule in vivo, we confirmed that the TIGIT+ Tregs 
from TILs are indeed major producers of IL-10 by examining the 
TIGIT+ and TIGIT– Tregs isolated from TILs of tumor-bearing 
IL-10/FOXP3 reporter mice (Figure 3B). We further found that 
other Treg effector molecules (Prf1, which encodes perforin, and 
TGF-β1) are also more highly expressed in TIGIT+ than in TIGIT– 
Tregs in TILs. Collectively, our data indicate that TIGIT+ Tregs in 
TILs exhibit a highly activated suppressor phenotype relative to 
their TIGIT– Treg counterparts. Indeed, we found that the TIGIT+ 
Tregs in TILs were more suppressive compared with the TIGIT– 
Tregs in TILs (Figure 3C).
late, as determined by surface expression of CD107a, when com-
pared with TIGIT– CD8+ TILs (Figure 2A). Together, these data 
show that TIGIT+ CD8+ TILs are dysfunctional and further suggest 
that, in addition to being poor mediators of tumor clearance, they 
may contribute to immune suppression locally in the tumor micro-
environment by virtue of their enhanced production of IL-10.
The accumulation of multiple coinhibitory receptors on the 
surface of T cells is associated with increased dysfunction (18). We 
therefore examined the expression of TIGIT in conjunction with 
other coinhibitory receptors (PD-1, LAG-3, and TIM-3) that have 
been associated with a dysfunctional phenotype in TILs (19–22). 
We found that TIGIT was coexpressed with PD-1, TIM-3, and 
LAG-3 on CD8+ TILs (Figure 2B). Interestingly, we observed that 
TIGIT was expressed on CD8+ TILs that exhibited the highest lev-
els of PD-1 and TIM-3. In chronic lymphocytic choriomeningitis 
virus (LCMV) infection, where T cell dysfunction has been well 
studied, it has been shown that high expression of PD-1 coincides 
with high expression of the transcription factor Eomes and that 
PD-1hi Eomeshi CD8+ T cells constitute a terminally exhausted sub-
set that exhibits severe dysfunction (23). Recently, PD-1hi Eomeshi 
CD8+ T cells have also been described in melanoma tumors and 
found to exhibit decreased function (24). As TIGIT coincides with 
high PD-1 expression on CD8+ TILs (Figure 2B), we examined 
whether these cells also exhibit high expression of eomes. Indeed, 
we found that TIGIT+ CD8+ TILs had significantly higher expres-
sion of eomes compared with that observed on TIGIT– CD8+ TILs 
(Figure 2C). Collectively, our data show that TIGIT+ CD8+ T cells 
constitute a highly dysfunctional subset within CD8+ TILs.
TIGIT+ Tregs exhibit a highly activated and suppressive pheno-
type in tumor tissue. Our data show that TIGIT expression within 
CD4+ TILs was almost exclusively on FOXP3+ Tregs (Figure 1B). 
Recently, TIGIT expression was shown to identify a cell popu-
Figure 2. TIGIT marks a dysfunctional 
CD8+ T cell subset. TILs were harvested 
from WT mice (n = 5–20) or IL-10 Thy1.1 
mice (n = 5) bearing B16F10 melanoma 
12–15 days after tumor implantation 
when tumor sizes measured between 
140 and 180 mm2. (A) Frequency ± SEM 
of CD8+ TIGIT+ and TIGIT– TILs producing 
IL-2, TNF-α, IFN-γ, and IL-10 (Thy1.1) or 
expressing surface CD107a after stimula-
tion with anti-CD3 and anti-CD28. Data 
were pooled from 3 different experiments. 
(B) Representative flow cytometric data 
showing TIGIT coexpression with PD-1, 
TIM-3, and LAG-3 on CD8+ TILs. Data are 
representative of 5 individual mice. (C) 
Left panel: representative contour plot 
showing TIGIT coexpression with eomes 
in CD8+ TILs. Middle panel: representative 
histogram showing eomes expression in 
TIGIT+ and TIGIT– CD8+ TILs. Right panel: 
mean fluorescence intensity (MFI) ± SEM 
for eomes in TIGIT+ and TIGIT– CD8+ TILs 
(n = 8 mice). Data were pooled from 2 
different experiments. ****P < 0.0001, 
***P < 0.001, **P < 0.01, and *P < 0.05 by 
Mann-Whitney U test.
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line TIGIT–deficient (Tigit–/–) mice. We found that TIGIT defi-
ciency significantly delayed the growth of both B16F10 mela-
noma and MC38 colon carcinoma relative to WT controls (Figure 
4A), indicating that TIGIT plays an inhibitory role in different 
tumor models. As TIGIT can be expressed by NK cells as well as 
by CD8+ T cells (4–6), we determined whether the enhanced anti-
tumor immunity observed in the absence of TIGIT was depen-
dent on CD8+ T cell or NK cell responses. Using depleting Abs, 
we found that CD8+ T cells, but not NK cells, were required for 
the improved control of tumor growth observed in the absence of 
TIGIT (Figure 4B). To address whether better control of tumor 
growth in the absence of TIGIT indeed correlated with increased 
function in CD8+ TILs, we examined antigen-specific responses 
in CD8+ TILs from mice bearing B16F10 melanoma tumors. We 
found that both the frequency of granzyme B+ cells as well as 
the expression level of granzyme B was increased in CD8+ TILs 
from Tigit–/– mice after stimulation (Figure 4C). We further exam-
ined the effect of TIGIT deficiency on antigen-specific cytokine 
responses in either B16F10 melanoma or MC38 colon carcinoma 
Among the genes upregulated in TIGIT+ Tregs in TILs, Havcr2 
was of particular interest, as we had previously found that TIM-3 
is uniquely enriched on Tregs that accumulate in tumor tissue and 
express high levels of both IL-10 and perforin (25). Examination of 
TIM-3 and TIGIT expression in Tregs from naive and tumor-bear-
ing mice showed that while TIM-3 was expressed on a fraction of 
TIGIT+ Tregs in naive mice, all of the TIGIT+ Tregs in tumor tissue 
expressed TIM-3, and at a much higher level than that observed 
in naive Tregs (Figure 3D). The potent upregulation of TIM-3 in 
tumor tissue, together with the highly active and suppressive Treg 
phenotype of TIGIT+ Tregs in tumor tissue, raises the possibility 
that the TIM-3 and TIGIT signaling pathways may cooperate to 
direct Treg function in tumor tissue.
Enhanced antitumor immunity in the absence of TIGIT. Our 
data show that TIGIT expression marks severely dysfunctional 
CD8+ TILs and tumor tissue Tregs that exhibit a highly activated 
and suppressive phenotype (Figures 2 and 3); however, they do 
not address whether TIGIT has a role in regulating antitumor 
immunity. To address this, we monitored tumor growth in germ-
Figure 3. TIGIT+ Tregs in the tumor tissue exhibit a more suppressive and activated phenotype. TIGIT+ and TIGIT– Tregs were isolated from B16F10 tumors 
implanted into Foxp3-GFP–KI mice (A, C, and D) or IL-10-Thy1.1 Foxp3-GFP–KI mice (B). (A) Gene expression was analyzed using a custom NanoString Code-
Set. Bar graphs show the fold expression ± SEM of selected differentially expressed surface receptors (left), effector molecules, and transcription factors 
(TFs) (right) in TIGIT+ and TIGIT– Tregs. Data are pooled from 2 different experiments. Selected genes with a fold change of greater than 2 are depicted. (B) 
Left panels: representative flow cytometric data showing IL-10-Thy1.1 staining in TIGIT– and TIGIT+ Treg TILs. Right panel: frequency ± SEM of IL-10+ cells 
within TIGIT– and TIGIT+ Treg TILs (n = 5). Data are representative of 2 independent experiments. **P < 0.01 by Mann-Whitney U test. (C) Tregs isolated 
from tumor tissue were cocultured with splenic CT Violet–labeled CD4+ T cells (1:8). CT Violet dilution was analyzed by flow cytometry 4 days later. Gates 
indicate the undivided CD4+ subsets. Data are representative of 2 experiments. (D) Representative contour plots of TIM-3 expression on TIGIT+ TIL Tregs or 
TIGIT+ naive Tregs. Data are representative of 5 individual mice.
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received Tigit–/– CD8+ T cells showed similar tumor growth com-
pared with mice that received WT CD8+ T cells (Figure 5A). We 
next addressed the role of TIGIT in Tregs by transferring WT 
or Tigit–/– (CD4+ FOXP3+) Tregs along with WT CD4+ effector 
(FOXP3–) and WT CD8+ effector T cells. In contrast to our obser-
vations in mice harboring TIGIT deficiency only in CD8+ T cells, 
we found that mice that received Tigit–/– Tregs exhibited signifi-
cantly delayed tumor growth compared with mice that received 
WT Tregs (Figure 5B). Given this difference in tumor growth, 
we examined whether lack of TIGIT in Tregs interfered with the 
development of a dysfunctional phenotype in CD8+ T cells. As 
TIGIT expression on CD8+ TILs correlated with a highly dysfunc-
tional phenotype (Figure 2), we determined TIGIT expression on 
CD8+ TILs in mice that received WT or Tigit–/– Tregs. We found a 
significant decrease in the frequency of TIGIT+ CD8+ TILs in mice 
harboring TIGIT deficiency in Tregs, indicating that the absence 
of TIGIT in Tregs restrains the development of a severe dysfunc-
tional phenotype in CD8+ TILs (Figure 5C). Indeed, we found 
that lack of TIGIT on Tregs resulted in significantly enhanced 
IL-2, TNF-α, and IFN-γ production by CD8+ TILs (Figure 5D). 
engineered to express low levels of OVA (MC38-OVAdim) (26) and 
observed a trend toward higher frequencies of IL-2–, TNF-α–, and 
IFN-γ–producing cells within TILs from TIGIT-deficient mice 
(Supplemental Figure 3, A and B). Last, we found that while WT 
CD8+ TILs exhibited little to no proliferation after stimulation 
with anti-CD3, Tigit–/– CD8+ TILs exhibited a heightened prolif-
erative response (Figure 4D). Collectively, these data support the 
idea that TIGIT limits antitumor T cell responses.
TIGIT+ Tregs regulate antitumor immunity. While our data 
support the idea that TIGIT has a role in the regulation of anti-
tumor CD8+ T cell responses (Figure 4), they do not elucidate 
whether TIGIT suppresses antitumor CD8+ T cells directly or 
indirectly via Tregs. To address this question, we established an 
adoptive transfer system using WT and TIGIT-deficient (Tigit–/–) 
T cells, wherein we could segregate the loss of TIGIT expression 
to either CD8+ T cells or CD4+ FOXP3+ Tregs. To address the role 
of TIGIT in CD8+ T cells, we adoptively transferred WT CD4+ T 
cells (FOXP3+ and FOXP3–) along with either WT or Tigit–/– CD8+ 
T cells into Rag-deficient (Rag–/–) mice that were subsequently 
implanted with B16F10 melanoma. We found that the mice that 
Figure 4. TIGIT restrains antitumor 
immune responses. (A) Growth of B16F10 
melanoma or MC38 colon carcinoma in WT 
or Tigit–/– mice (n = 5–6). Data are repre-
sentative of 3 independent experiments. 
***P < 0.001 and ****P < 0.0001  
by repeated-measures ANOVA with a 
Sidak test. (B) WT or Tigit–/– mice (n = 5)  
were treated i.p. with anti-asialoGM1 
or anti-CD8β Abs or with their isotype 
controls (cIg) on days –1, 0, 7, and 14 after 
B16F10 tumor implantation. Tumor growth 
after anti-asialoGM1 (left) or anti-CD8β 
(right) treatment is shown. Data are repre-
sentative of 2 independent experiments. 
Comparisons are between WT plus cIg 
versus Tigit–/–, irrespective of cIg or anti- 
asialoGM1 treatment (left), and between 
cIg versus anti-CD8β in Tigit–/– mice (right). 
***P < 0.001 and ****P < 0.0001  
by repeated-measures ANOVA with a 
Sidak test. (C and D) Total TILs were 
isolated from B16F10 tumor–bearing WT 
or Tigit–/– mice (n = 4–5). (C) TILs were 
stimulated with 10 μg/ml gp100 peptide. 
Contour plots and bar graphs show the 
percentage ± SEM of granzyme B+ cells 
and the normalized MFI of granzyme B 
expression within CD8+ TILs. MFI was nor-
malized to the mean of WT CD8+ TILs  
in each independent experiment. Data 
were pooled from 2 to 3 experiments.  
*P < 0.05 and **P < 0.01 by Mann-Whit-
ney U test. (D) CT Violet–labeled TILs were 
stimulated with anti-CD3 for 4 days and 
then analyzed by flow cytometry. Repre-
sentative histogram of CT Violet dilution 
in CD8+ TILs. Data are representative of 3 
individual measurements.
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Last, we found that the frequency of gp100-specific CD8+ T cells 
was also increased in mice harboring TIGIT deficiency only in 
Tregs, suggesting that the maintenance and/or survival of anti-
gen-specific CD8+ T cells is enhanced in the absence of TIGIT 
on Tregs (Figure 5E). Together, these data indicate that TIGIT 
dampens antitumor immunity predominantly by regulating Treg 
function, which in turn promotes the development of a severe 
dysfunctional phenotype in CD8+ T cells.
TIGIT signaling in Tregs. Our data support a key role for TIGIT 
in suppressing antitumor immunity via its role in Tregs. This raises 
the important question of how TIGIT signaling alters the Treg 
phenotype. While our examination of the gene expression pro-
file of TIGIT+ Tregs in TILs showed increased expression of Treg 
effector molecules and upregulation of some distinct genes rela-
tive to TIGIT– Tregs (Figure 3), it did not address whether engage-
ment of TIGIT is responsible for driving the differential expres-
sion of any of these genes. The likelihood that TIGIT is actively 
engaged in the tumor environment is high, given our observation 
of the elevated expression levels of TIGIT ligands on tumor cells 
(Supplemental Figure 1). To address the possibility that TIGIT 
engagement might modulate the Treg phenotype in tumor tissue, 
we identified the genes that are downstream of TIGIT signaling 
in Tregs. For this, we used an agonistic anti-TIGIT Ab that was 
previously shown to bind to TIGIT and inhibit T cell proliferation 
(9). We stimulated Tregs in vitro in the presence of the agonistic 
anti-TIGIT Ab and examined gene expression at 2 different time 
points (48 and 96 hours) using NanoString nCounter technology 
as described above. We found several genes that were modulated 
in Tregs as a consequence of TIGIT signaling (Figure 6). We also 
found that the transcription factors Eomes, Irf8, Prdm1, Tbx21, 
and Runx2 were induced by TIGIT signaling in Tregs. TIGIT liga-
tion also upregulated expression of the chemokine Ccl4 and the 
chemokine receptors Cxcr3 and Ccr8. The upregulation of Cxcr3 
and Tbx21 indicates that TIGIT signaling may direct suppressor 
function toward IFN-γ–producing T cells, as T-bet+ CXCR3+ Tregs 
have been shown to control Th1 type inflammation in vivo (27). 
The upregulation of CCR8 and CCL4 indicates that TIGIT signal-
ing may promote Treg migration and retention in tumor tissue (28, 
29). Interestingly, TIGIT signaling decreased expression of TCF7, 
which has recently been shown to antagonize the FOXP3-driven 
transcriptional program in Tregs (30). Thus, TIGIT signaling in 
Tregs may favor Treg stability. In line with this observation, TIGIT 
expression has recently been shown to correlate strongly with a 
stable Treg phenotype in humans (14). Importantly, several of the 
Figure 5. TIGIT expression on Tregs has a dominant role compared with CD8+ T cells in regulating antitumor responses. (A) CD8+ T cells from WT or Tigit–/– 
mice were mixed with WT CD4+ (FOXP3+ and FOXP3–) T cells and injected i.v. into Rag–/– mice (n = 5). Two days later, mice were implanted with B16F10 tumor 
cells. Graph shows tumor growth over time. Data are representative of 3 different experiments. (B) Tregs from WT or Tigit–/– Foxp3-GFP–KI mice were mixed 
with WT CD8+ and CD4+ FOXP3– cells and transferred into Rag–/– mice (n = 5). Graph shows tumor growth over time. Data are representative of 5 different 
experiments. ***P < 0.001 by repeated-measures ANOVA with a Sidak test. (C–E) Seventeen days after implantation, TILs and DLNs were isolated from 
mice that received WT or Tigit–/– Tregs. (C) Frequency ± SEM of TIGIT+ CD8+ TILs from each group (n = 9–10). Data were pooled from 2 independent experi-
ments. (D) TILs were stimulated with anti-CD3 and anti-CD28 and analyzed for cytokine production. Graphs show IL-2+, TNF-α+, and IFN-γ+ percentages ± 
SEM within CD8+ TILs in each group (n = 4–5). *P < 0.05 by Mann-Whitney U test (C and D). (E) Representative plots show gp33 (control dextramer) or gp100 
dextramer staining in CD8+ T cells from pooled DLNs of Rag–/– mice. (D and E) Data are representative of 2 independent experiments.
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genes we identified as modulated upon TIGIT signaling in Tregs 
(Tbx21, Ccr8, Ccl4, Cxcr3, Prdm1, Runx2, Klf3, Bcl2, and Tcf7) were 
among the genes we observed as differentially regulated in TIGIT+ 
relative to TIGIT– Tregs from TILs (Figure 3A and Supplemental 
Table 1). Collectively, these data support the notion that TIGIT 
actively signals in Tregs to modulate the Treg phenotype and that 
TIGIT is actively engaged in vivo in the tumor microenvironment.
TIGIT synergizes with TIM-3. Our data showing TIM-3 upregu-
lation on TIGIT+ Tregs in tumor tissue (Figure 3), together with our 
data indicating the dominant function of TIGIT in Tregs in sup-
pressing antitumor immunity (Figure 5), raised the possibility that 
the TIGIT and TIM-3 pathways might act synergistically to drive 
suppression in the tumor environment. We therefore examined 
the effect of TIM-3 blockade in the absence of TIGIT and found 
that treatment of Tigit–/– mice with anti–TIM-3 Abs significantly 
decreased tumor growth compared with Tigit–/– deficiency alone 
(Figure 7A). As observed in WT versus Tigit–/– mice (Figure 4B), 
the synergistic effect of anti–TIM-3 in Tigit–/– mice required CD8+ 
T cells but not NK cells (Supplemental Figure 4). We further tested 
anti–TIM-3 in Tigit–/– and WT mice in 2 different models of exper-
imental tumor metastasis and found that TIM-3 blockade further 
reduced the number of foci in the lungs of Tigit–/– mice (Figure 7B). 
Last, TIM-3 blockade increased survival over that observed with 
TIGIT deficiency alone in a B16F10 melanoma lung metastasis 
model (Figure 7C). Collectively, these data support the idea that 
TIM-3 and TIGIT cooperate to suppress antitumor responses.
Discussion
Our data add a dimension to our current understanding of how 
TIGIT modulates antitumor immunity by showing that the func-
tion of TIGIT in Tregs is dominant over its function in CD8+ T 
cells. This observation runs counter to the emphasis on the role of 
coinhibitory receptors in suppressing antitumor immunity via the 
direct promotion of a dysfunctional phenotype in CD8+ T cells. 
Instead, our data suggest that TIGIT signaling induces a molecular 
program in Tregs that in turn drives the development of a dysfunc-
tional phenotype in CD8+ T cells. This observation is in line with our 
previous study showing that the dysfunctional phenotype of CD8+ 
TILs is diminished after Treg depletion (25) and with a recent study 
showing that Tregs modify the tumor microenvironment to pro-
mote CD8+ T cell dysfunction (31). Similarly, Tregs have recently 
been shown to play an important role in the maintenance of T cell 
dysfunction in chronic LCMV infection (32). Thus, a key function 
of Tregs in chronic disease settings may be to drive the dysfunc-
tional phenotype in effector CD8+ T cells in order to prevent immu-
nopathology. Our data indicate that TIGIT signaling may be critical 
for the role of Tregs in driving CD8+ T cell dysfunction.
One possible mechanism by which TIGIT+ Tregs can drive a 
dysfunctional phenotype in effector T cells is via their high pro-
duction of IL-10. Our data show that IL-10 is among the genes 
most highly upregulated in TIGIT+ Tregs that infiltrate tumor 
tissue. Indeed, IL-10 has been linked to viral persistence and the 
development of T cell dysfunction in chronic LCMV infection 
(33, 34). Further elucidation of the transcriptome of TIGIT+ Tregs 
from tumor tissue will likely identify other potential mechanisms 
by which TIGIT+ Tregs can drive T cell dysfunction.
The dominant function of TIGIT in Tregs in immune regula-
tion is reminiscent of the role of CTLA-4 on Tregs. CTLA-4 has 
been shown to be critical for the maintenance of Treg suppressor 
function (35). However, unlike CTLA-4, which is expressed on all 
Tregs, TIGIT is only expressed on a subset of normal circulating 
Tregs (12) and, as we show here, is highly enriched on the Tregs that 
infiltrate tumor tissue. The enriched expression of TIGIT in tumor 
tissue positions TIGIT as a more precise molecular target than is 
CTLA-4. Thus, therapies that target TIGIT would be expected to 
result in fewer unwanted systemic effects than would those that 
target CTLA-4 (2) and function via Treg depletion (36–38).
Importantly, our data do not exclude a direct role for TIGIT 
in promoting a dysfunctional phenotype in CD8+ T cells. Indeed, 
it is possible that the combined loss of TIGIT in Tregs and CD8+ T 
cells would have an even stronger effect on tumor immunity than 
would loss of TIGIT in Tregs alone. The fact that TIGIT deficiency 
in CD8+ T cells alone does not result in improved antitumor immu-
nity likely reflects compensation by other coinhibitory receptors 
that are functionally redundant with TIGIT. Functional redun-
dancy across coinhibitory receptor pathways would not be surpris-
ing in the tumor microenvironment, where there is strong pressure 
to keep CD8+ T cell responses suppressed and CD8+ T cells express 
multiple coinhibitory receptors. Indeed, such functional redun-
dancy forms the basis for why coblockade of coinhibitory recep-
tors has been shown to be more effective in both preclinical cancer 
models and the clinic (39–41).
A recent study suggests that TIGIT regulates T cell function 
by inhibiting CD226 dimerization and downstream signaling (15). 
Our study does not exclude this possibility. Rather, our data sup-
port the notion that TIGIT signaling drives a cell-intrinsic gene pro-
gram in Tregs that suppresses antitumor effector T cell responses. 
In addition to Treg-intrinsic TIGIT signaling, it is also possible that 
Figure 6. TIGIT signaling in Tregs. CD4+ FOXP3+ Tregs from WT Foxp3-GFP–KI mice were sorted and stimulated with plate-bound isotype or agonistic anti-
TIGIT Ab, together with anti-CD3 and anti-CD28, for 48 or 96 hours. Gene expression was then analyzed using a NanoString CodeSet. Bar graphs show the 
fold expression ± SEM of genes in Ab-treated versus isotype-treated cells at 48 and 96 hours. Data were pooled from 2 different experiments.
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Cell lines. CT26, B16F10, LLC, and MC38 cell lines were pur-
chased from ATCC. MC38-OVAdim was derived from MC38 as previ-
ously described (26).
Isolation of TILs. TILs were isolated by dissociating tumor tissue 
in the presence of collagenase D (2.5 mg/ml) for 20 minutes prior to 
centrifugation on a discontinuous Percoll gradient (GE Healthcare). 
Isolated cells were then used in various assays of T cell function. Cells 
were cultured in DMEM supplemented with 10% (vol/vol) FCS, 50 μM 
2-mercaptoethanol, 1 mM sodium pyruvate, nonessential amino acids, 
L-glutamine, and 100 U/ml penicillin and 100 μg/ml streptomycin.
Flow cytometry. Single-cell suspensions were stained with Abs 
against surface molecules. CD4 (clone RM4-5), CD8 (clone 53-6.7), and 
PD-1 (clone RMP1-30) Abs were purchased from BioLegend. LAG-3 
(clone C9B7W) and TIGIT (clone GIGD7) Abs were purchased from 
eBioscience. TIM-3 (clone 5D12) Ab was generated in-house. Staining 
with gp100 dextramers (Immudex) was done according to the manu-
facturer’s protocol. Fixable viability dye eF506 (eBioscience) was used 
to exclude dead cells. For CD107a staining, TILs were stimulated with 
anti-CD3 (0.5 μg/ml) and anti-CD28 (0.25 μg/ml) (BioLegend) for 
4 hours in the presence of Golgi stop (BD Biosciences) and CD107a 
Ab (clone 1D4B) (BioLegend). For intracytoplasmic cytokine stain-
ing, cells were stimulated with anti-CD3 and anti-CD28 as described 
above. For granzyme B staining, TILs from B16F10 tumors were stim-
ulated with 10 μg/ml hgp100, harvested, and stained with Abs against 
surface proteins prior to fixation and permeabilization. Permeabilized 
cells were then stained with Abs against IL-2 (clone JES6-5H4), TNF-α 
(clone MP6-XT22), IFN-γ (clone XMG-1.2) (eBioscience), or granzyme 
B (clone 2C5/F5; BD Pharmingen). For IL-10 detection, TILs were iso-
lated from IL-10 Thy1.1 reporter mice, and after 4 hours of stimulation, 
the interaction of TIGIT with CD155 on antigen-presenting cells 
(APCs) in the tumor environment has an important role in regulat-
ing antitumor immunity. Indeed, Tregs are known to modify the DC 
phenotype (42), and TIGIT engagement of CD155 in DCs has been 
shown to inhibit IL-12 and enhance IL-10 production (4). Whether 
TIGIT+ Tregs interact with tumor-associated DCs and induce them 
to become tolerogenic will be the subject of future studies.
The distinct role TIGIT plays in different subsets of TILs is an 
important consideration for combinatorial immunotherapeutic 
approaches involving TIGIT blockade. A recent study showed that 
anti-TIGIT controls tumor growth much more efficiently when 
combined with anti–PD-1 (15). In light of our data, the remarkable 
efficacy of TIGIT/PD-1 coblockade could reflect the combined 
effect of direct modulation of dysfunctional CD8+ T cells, together 
with modulation of highly suppressive intratumoral Tregs. Our 
data further suggest that cotargeting TIGIT and TIM-3 could be 
another potent combined immunotherapeutic approach. Further 
investigation will be required to determine whether the TIGIT, 
PD-1, and TIM-3 pathways synergize at the cellular level in CD8+ 
T cells, Tregs, or both. Our observations broaden the current per-
spective of how therapies that target the coinhibitory receptor 
TIGIT modulate antitumor immunity.
Methods
Mice. Six- to eight-week-old female BALB/c, C57BL/6, and Rag2–/– mice 
were purchased from The Jackson Laboratory. Foxp3-GFP–knockin 
(KI) reporter mice (43), IL-10–CD90.1 reporter mice (44), and Tigit–/– 
mice (10) were previously described. Tigit–/– mice were provided by 
ZymoGenetics (Bristol-Myers Squibb).
Figure 7. TIM-3 and TIGIT synergize to suppress antitumor immunity. (A) WT and Tigit–/– mice (n = 5) were implanted s.c. with B16F10 melanoma cells 
and treated with 250 μg isotype or anti–TIM-3 (RMT3-23) Ab on days 3, 6, 9, and 12. Statistical comparisons are between WT plus Ig and Tigit–/– plus Ig and 
between Tigit–/– plus Ig and Tigit–/– plus anti–TIM-3. ****P < 0.0001 by repeated-measures ANOVA with a Sidak test. Data are representative of 2 experi-
ments. (B and C) B16F10 melanoma cells or RM-1 cells were administered i.v. to WT mice (n = 5 per group) that were treated i.p. with 250 μg isotype (cIg) 
and/or anti–TIM-3 (RMT3-23) Ab on days 0 and 3. (B) Graphs show the number of foci ± SEM in the lungs after B16F10 (left) or RM-1 (right) cell injections on 
day 14. Statistical comparisons are between Tigit–/– plus cIg and Tigit–/– plus anti–TIM-3. **P < 0.01 by Mann-Whitney U test. Data are representative of 2 
experiments. (C) Survival of mice (n = 10 per group) after i.v. administration of B16F10 melanoma cells. Statistical comparisons are between WT plus cIg and 
Tigit–/– plus cIg and between Tigit–/– plus cIg and Tigit–/– plus anti–TIM-3. ***P < 0.001 by log-rank test. Data were pooled from 2 independent experiments.
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with a custom-made CodeSet. Barcodes were counted (1,150 fields of 
view per sample) on an nCounter Digital Analyzer following the man-
ufacturer’s protocol (NanoString Technologies Inc.). Data were pro-
cessed first by normalization with respect to the geometric mean of 
the positive control spike counts (provided by the manufacturer) and 
then with 4 reference genes (Actb, Gapdh, Hprt, and Tubb5). A back-
ground correction was done by subtracting the mean plus 2 SDs of the 
8 negative control counts (provided by the manufacturer) and elimi-
nating data that were less than 1.
Statistics. Statistical differences were determined using GraphPad 
Prism software. Statistical significance was calculated by Mann-Whit-
ney U test for pair-wise comparisons. For multiple comparisons, a 
1-way ANOVA test was performed, and pair-wise significance was 
determined by Tukey’s multiple comparisons test. For assessment 
of the differences between tumor growth curves, significance was 
calculated by a repeated-measures ANOVA test, followed by a Sidak 
correction test. Statistical differences between survival curves were 
calculated by log-rank test. Values of P < 0.0001, P < 0.001, P < 0.01, 
and P < 0.05 were considered statistically significant.
Study approval. All experiments involving laboratory animals were 
performed under protocols approved by the Harvard Medical Area 
Standing Committee on Animals (Boston, Massachusetts, USA) and 
the QIMR Berghofer Animal Ethics Committee (Brisbane, Queens-
land, Australia).
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cells were stained with Abs against Thy1.1 (clone OX-7; BioLegend). For 
eomes staining, cells were stained with Abs against surface proteins 
and fixed and permeabilized with an eBioscience FOXP3 staining kit 
and then stained with anti-Eomes (clone Dan11mag) Ab (eBioscience). 
To assess cell proliferation, TILs were labeled with CellTrace (CT) Vio-
let (Life Technologies) and stimulated with 0.5 μg/ml anti-CD3 for 4 
days and then stained and analyzed by flow cytometry. All data were 
collected on a BD LSR II flow cytometer (BD Biosciences) and analyzed 
with FlowJo software.
Suppression assay. Tregs were isolated from tumor tissue of Foxp3- 
GFP–KI reporter mice by cell sorting on a BD FACSAria. Effector 
CD4+ T cells were isolated from spleens of WT unimmunized mice 
with anti-CD4 beads (Miltenyi Biotec) and labeled with CT Violet 
dye. Tregs were cocultured with effector CD4+ T cells at a 1:8 ratio. 
Irradiated splenic APCs were added to cocultures at a 5:1 ratio (APC/
effector CD4+) with anti-CD3 (1 μg/ml). Cells were analyzed by flow 
cytometry 4 days later.
Tumor experiments. CT26 and MC38 (1 × 106) or B16F10 (5 × 105) 
cells were implanted s.c. into the right flank. Tumor size was measured 
in 2 dimensions by caliper and is expressed as the product of 2 perpen-
dicular diameters. In some experiments, mice were treated i.p. with 
100 μg anti-asialoGM1 or anti-CD8β (clone 53.5.8; BioLegend) Abs or 
with their isotype controls (cIg) on days –1, 0, 7, and 14 after B16F10 
implantation. In some experiments, mice were treated with 250 μg iso-
type (rat IgG2a) or anti–TIM-3 (clone RMT3-23; Bio X Cell) Abs on the 
days indicated in the legend for Figure 7. In some experiments, 1 × 105 
B16F10 melanoma cells or RM-1 prostate cancer cells were adminis-
tered i.v. to WT mice. Metastatic burden was quantified by counting 
the number of foci on the surface of the lungs 14 days after injection. 
In some experimental metastatic model experiments, mice were mon-
itored to determine survival.
Adoptive transfers. For adoptive transfer experiments, CD4+ 
(FOXP3+ and FOXP3–) and CD8+ T cells from either WT or Tigit–/– 
Foxp3-GFP–KI reporter mice were isolated by cell sorting using a BD 
FACSAria. A total of 1.5 × 106 cells at a ratio of 1:0.5:0.01 (CD4/CD8/
Treg) was mixed in PBS and injected i.v. into Rag–/– mice. Two days 
later, mice were implanted with B16F10 melanoma cells and followed 
for tumor growth.
Analysis of gene expression by NanoString. CD4+ FOXP3+ TIGIT+ and 
TIGIT– cells were isolated by cell sorting from the TILs of Foxp3-GFP–
KI mice bearing B16F10 melanoma tumors on day 10 after tumor 
implantation. For the examination of TIGIT signaling, CD4+ FOXP3+ 
cells from naive Foxp3-GFP–KI mice were isolated by cell sorting 
and stimulated with plate-bound anti-CD3 (1 μg/ml) and anti-CD28 
(2 μg/ml), together with either agonist anti-TIGIT (4D4, generated 
in-house, ref. 9) (50 μg/ml) or isotype control. After 48 and 96 hours, 
cells were lysed in RLT lysis buffer (QIAGEN) and lysates hybridized 
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